| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/25/2009 | CN100471487C Method of extracting medicament possessing blood supplement spirit quiet boasting and calming functrous from pure Chinese medical preparation |
| 03/24/2009 | US7507841 Cannabinoid receptor modulator |
| 03/24/2009 | US7507824 Spiro(2H-1benzopyran-2,4′-piperidine) derivates as glycine transport inhibitors |
| 03/24/2009 | US7507816 Compounds for treatment of inflammation, antidepressants, nervous system disorders, cardiovascular disorders or analgesics from mannich reaction |
| 03/24/2009 | US7507798 Antibody specific for mutant presenilin 1 |
| 03/24/2009 | US7507767 Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity |
| 03/24/2009 | US7507759 Methods of using(+)-2-[1-(3-ethoxy-4methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3,-dione |
| 03/24/2009 | US7507758 4-alkyl-/4-alkenyl-/4-alkynyl methyl/-1-aryl-cyclohexylamine compounds |
| 03/24/2009 | US7507753 Biaryl compound and use thereof |
| 03/24/2009 | US7507744 Spiroazabicyclic heterocyclic compounds |
| 03/24/2009 | US7507743 Substituted 8′-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one and 8′-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one derivatives |
| 03/24/2009 | US7507730 Substituted pyrazolo[1,5-a]pyrimidines as potassium channel activators |
| 03/24/2009 | US7507729 Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives |
| 03/24/2009 | US7507728 for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; 10-chloro-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine; ligands; GABA A alpha 5 receptor inhibitors; halogenation |
| 03/24/2009 | US7507720 5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 03/24/2009 | US7507717 Inhibitors of neuronal amine transporters of neurotransmitters, such as noradrenaline, serotonin, dopamine, glutamic acid and glycine; pain, inflammation, incontinence, cardiovascular conditions and mood disorders |
| 03/24/2009 | US7507711 A PKC V5 isozyme-specific peptide, or a modification, derivation, fragment, combination, or hybrid thereof |
| 03/24/2009 | US7507542 Autoimmune diseases; inflammatory bowel disease; multiple sclerosis; rheumatic diseases; modulate gene expression |
| 03/24/2009 | US7507414 Therapeutic polypeptide with prolonged shelf-life and increased half life for use in treatment of cell proliferative, cardiovascular, inflammatory and autoimmune disorders |
| 03/24/2009 | US7507398 Using condensation aerosol (MMAD of less than 5 microns) formed by vaporizing a thin layer of the drug on a solid support and condensing the vapor to treat anxiety, vertigo, alcohol or nicotine withdrawal, sedation, hot flashes, peptic ulcers or for hormone replacement therapy, or pregnancy prevention |
| 03/24/2009 | US7507397 Delivery of muscle relaxants through an inhalation route |
| 03/24/2009 | CA2487586C Feed supplemented with ketoprofen and its use in the simultaneous treatment of conditions causing fever, inflammation and/or pain in a herd of animals |
| 03/24/2009 | CA2422380C Pyrazole compounds useful as protein kinase inhibitors |
| 03/24/2009 | CA2382404C Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 03/24/2009 | CA2352211C Sustained release matrix systems for highly soluble drugs |
| 03/24/2009 | CA2267456C Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| 03/24/2009 | CA2136969C Prevention and treatment of peripheral neuropathy |
| 03/19/2009 | WO2009036322A1 Use of propofol prodrugs for treating neuropathic pain |
| 03/19/2009 | WO2009036149A2 Methods for treatment of degenerative disease associated with apoptosis |
| 03/19/2009 | WO2009036144A1 Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists |
| 03/19/2009 | WO2009036132A1 Octahydro-pyrrolo[3,4-b]pyrrole n-oxides |
| 03/19/2009 | WO2009036117A1 Azacyclylisoquinolinone and isoindolinone derivatives as histamine-3 antagonists |
| 03/19/2009 | WO2009036108A1 Methods and compositions for inhibiting vascular leakage |
| 03/19/2009 | WO2009035684A1 Spirocyclic aminoquinolones as gsk-3 inhibitors |
| 03/19/2009 | WO2009035634A2 Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors |
| 03/19/2009 | WO2009035473A2 Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
| 03/19/2009 | WO2009035162A1 6-pyrimidinyl-pyrimid-2-one derivative |
| 03/19/2009 | WO2009035159A1 3-methyl-2- ( (2s) -2- (4- (3-methyl-1, 2, 4-oxadiazol-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor |
| 03/19/2009 | WO2009035055A1 Insulin-like growth factor-1 (igf-1) production promoter |
| 03/19/2009 | WO2009034976A1 Alkylsulfone derivative |
| 03/19/2009 | WO2009034581A1 Substituted indolyl compounds and their use as 5-ht6 ligands |
| 03/19/2009 | WO2009034475A2 Perharidines as cdk inhibitors |
| 03/19/2009 | WO2009034411A1 Perharidines as cdk inhibitors |
| 03/19/2009 | WO2009034380A1 Piperidine derivatives as agonists of muscarinic receptors |
| 03/19/2009 | WO2009034232A1 Preparation and a component intended to be added to a tobacco product |
| 03/19/2009 | WO2009034127A1 Use of the cyp46a1 gene for the treatment of alzheimer's disease |
| 03/19/2009 | WO2009034062A1 Compounds which inhibit the glycine transporter and uses thereof in medicine |
| 03/19/2009 | WO2009034061A1 Spiro-condensed imidazolone derivatives inhibiting the glycine transporter |
| 03/19/2009 | WO2009034043A1 Novel phenoxazin-3-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/19/2009 | WO2009034042A1 Novel benzooxazol- and benzooxathiol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/19/2009 | WO2009034028A2 Novel compounds |
| 03/19/2009 | WO2009033995A1 Piperidine derivatives as nk3 receptor antagonists |
| 03/19/2009 | WO2009033824A1 Use of a combination of beta-casokinin and cnp-22 as a therapeutic agent |
| 03/19/2009 | WO2009033823A1 Use of a peptide combination comprising urotensin ii as a therapeutic agent |
| 03/19/2009 | WO2009033822A2 Use of a combination of a cathepsin g fragment and teprotide as a therapeutic agent |
| 03/19/2009 | WO2009033821A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033820A2 Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis |
| 03/19/2009 | WO2009033819A2 Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids |
| 03/19/2009 | WO2009033818A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033817A2 Use of the combination of the hcv-1 e2 protein (484-499) and the human pancreatic polypeptide as a therapeutic agent |
| 03/19/2009 | WO2009033816A2 Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent |
| 03/19/2009 | WO2009033815A2 Use of the peptide combination ala-pro-gly-pro-arg with cecropin a as a therapeutic agent |
| 03/19/2009 | WO2009033814A2 Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent |
| 03/19/2009 | WO2009033813A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033812A2 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent |
| 03/19/2009 | WO2009033811A2 Therapeutic uses of muroctasin and kisspeptin13 and compositions thereof |
| 03/19/2009 | WO2009033810A2 Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection |
| 03/19/2009 | WO2009033809A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033808A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033807A2 Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43 |
| 03/19/2009 | WO2009033806A2 Use of gly-pro-glu-oh (gpe) as a therapeutic agent |
| 03/19/2009 | WO2009033805A2 Use of somatostatin-14 as a therapeutic agent |
| 03/19/2009 | WO2009033804A2 Use of gamma- endorphin as a therapeutic agent |
| 03/19/2009 | WO2009033803A2 Use of the pentapeptide drlds and gamma-endorphin as therapeutic agents |
| 03/19/2009 | WO2009033802A2 Antide as a therapeutic agent |
| 03/19/2009 | WO2009033801A2 Syndyphalin alone or in combination with antide as a therapeutic agent |
| 03/19/2009 | WO2009033800A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033799A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033798A1 Combination of motilin and minigastrin as a therapeutic agent |
| 03/19/2009 | WO2009033797A2 Use of apelin-17 and peptide yy as therapeutic agents, eg for treating hbv infection |
| 03/19/2009 | WO2009033796A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033793A2 Pentagastrin as a therapeutic agent |
| 03/19/2009 | WO2009033792A2 Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent |
| 03/19/2009 | WO2009033791A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033790A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033787A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033786A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033785A2 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection |
| 03/19/2009 | WO2009033784A2 Use of apelin-13 (qrprlshkgpmpf) and optionally aplha-casein (90-96) as a therapeutic agents in eg the treatment of hiv infection |
| 03/19/2009 | WO2009033783A2 Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis |
| 03/19/2009 | WO2009033782A2 Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis |
| 03/19/2009 | WO2009033781A2 Use of k237 as therapeutic agent |
| 03/19/2009 | WO2009033780A2 Use of growth hormone-releasing factor and/or k237 as a therapeutic agents |
| 03/19/2009 | WO2009033778A2 Mage-3 antigen and others for use as a therapeutic agent |
| 03/19/2009 | WO2009033777A1 Leuprolide analog as a therapeutic agent |
| 03/19/2009 | WO2009033776A1 Use of a defensin peptide as a therapeutic agent |
| 03/19/2009 | WO2009033775A2 Peptide alpmhir alone or in combination with peptide yvpfppf as therapeutic agent |
| 03/19/2009 | WO2009033772A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033771A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033770A2 Calcitonin c-terminal flanking peptide for use as a therapeutic agent |